Impact of <i>KRAS</i> codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab
In conclusion, no significant associations between KRAS-G12 and overall survival were found for TAS-102 or TAS-Bev. Further research is needed to assess the impact of these mutations on combined TAS-Bev therapy prior to any clinical application.
Authors
- Jane E. Rogers (ORCID: https://orcid.org/0000-0002-7275-7008)
- Arvind Dasari
- Hey Min Lee (ORCID: https://orcid.org/0000-0001-7792-4226)
- Scott Kopetz
- Sara Lonardi (ORCID: https://orcid.org/0000-0002-7593-8138)
- Ymke van der Pol (ORCID: https://orcid.org/0000-0002-3040-5848)
- Stacy Diao (ORCID: https://orcid.org/0000-0002-3429-310X)
- Justin Guinney (ORCID: https://orcid.org/0000-0003-1477-1888)
- Oscar E. Villarreal (ORCID: https://orcid.org/0000-0002-4138-2696)
- Giulia Maddalena (ORCID: https://orcid.org/0000-0002-1714-1171)
- Zach Rivers
- Oluwadara Coker
- Wendy Covert
- Kanwal Raghav
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Istituto Oncologico Veneto (IT)
- Tempus Labs (United States) (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1093/jnci/djaf385
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00